Literature DB >> 8873775

Neurocognitive deficits and social functioning in outpatients with schizophrenia.

F Dickerson1, J J Boronow, N Ringel, F Parente.   

Abstract

Previous studies suggest that neurocognitive factors may contribute to the reduced social functioning of patients with schizophrenia. To assess this relationship, we administered a battery of neurocognitive tests and independently assessed symptoms (PANSS) and social functioning (SFS) in 88 stable outpatients with schizophrenia. We found a significant correlation between neurocognitive and social functioning variables. Patients' performance on aphasia, spatial organization and visual spatial tasks was correlated with their competence at activities of daily living, frequency of social activities and total social functioning. Regression analyses of each social functioning scale revealed different symptom and neurocognitive predictors. Patients' overall social functioning was best predicted by a combination of negative symptoms and aphasia. The results support the potential use of interventions to reduce patients' cognitive deficits as a means to improve their social outcomes.

Entities:  

Mesh:

Year:  1996        PMID: 8873775     DOI: 10.1016/0920-9964(96)00040-0

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  15 in total

Review 1.  Sources of heterogeneity in schizophrenia: the role of neuropsychological functioning.

Authors:  B E Seaton; G Goldstein; D N Allen
Journal:  Neuropsychol Rev       Date:  2001-03       Impact factor: 7.444

2.  Exposure to Epstein Barr virus and cognitive functioning in individuals with schizophrenia.

Authors:  Faith Dickerson; Emily Katsafanas; Andrea Origoni; Amalia Squire; Sunil Khushalani; Theresa Newman; Kelly Rowe; Cassie Stallings; Christina L G Savage; Kevin Sweeney; Tanya T Nguyen; Alan Breier; Donald Goff; Glen Ford; Lorraine Jones-Brando; Robert Yolken
Journal:  Schizophr Res       Date:  2021-01-12       Impact factor: 4.939

3.  Prediction of community outcome in schizophrenia 1 year after discharge from inpatient treatment.

Authors:  Andreas Wittorf; Georg Wiedemann; Gerhard Buchkremer; Stefan Klingberg
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-11-07       Impact factor: 5.270

Review 4.  Determinants of functioning and well-being among individuals with schizophrenia: an integrated model.

Authors:  P T Yanos; R H Moos
Journal:  Clin Psychol Rev       Date:  2006-02-09

5.  Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder.

Authors:  L Elliot Hong; Gunvant K Thaker; Robert P McMahon; Ann Summerfelt; Jill Rachbeisel; Rebecca L Fuller; Ikwunga Wonodi; Robert W Buchanan; Carol Myers; Stephen J Heishman; Jeff Yang; Adrienne Nye
Journal:  Arch Gen Psychiatry       Date:  2011-08-01

6.  F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. III. Activity in models of cognition and negative symptoms.

Authors:  R Depoortère; A L Auclair; L Bardin; L Bruins Slot; M S Kleven; F Colpaert; B Vacher; A Newman-Tancredi
Journal:  Br J Pharmacol       Date:  2007-03-20       Impact factor: 8.739

Review 7.  Cognitive control deficits in schizophrenia: mechanisms and meaning.

Authors:  Tyler A Lesh; Tara A Niendam; Michael J Minzenberg; Cameron S Carter
Journal:  Neuropsychopharmacology       Date:  2010-09-15       Impact factor: 7.853

8.  Social functioning in individuals at clinical high risk for psychosis.

Authors:  Jean Addington; David Penn; Scott W Woods; Donald Addington; Diana O Perkins
Journal:  Schizophr Res       Date:  2007-11-19       Impact factor: 4.939

9.  Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia.

Authors:  Viviane Labrie; Tatiana Lipina; John C Roder
Journal:  Psychopharmacology (Berl)       Date:  2008-07-03       Impact factor: 4.530

10.  Predicting schizophrenia patients' real-world behavior with specific neuropsychological and functional capacity measures.

Authors:  Christopher R Bowie; Winnie W Leung; Abraham Reichenberg; Margaret M McClure; Thomas L Patterson; Robert K Heaton; Philip D Harvey
Journal:  Biol Psychiatry       Date:  2007-07-27       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.